Collegium Pharmaceutical
COLL
278 hedge funds and large institutions have $1.72B invested in Collegium Pharmaceutical in 2025 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 85 increasing their positions, 108 reducing their positions, and 16 closing their positions.
225% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 16
33% more capital invested
Capital invested by funds: $1.3B → $1.72B (+$422M)
14% more funds holding
Funds holding: 244 → 278 (+34)
0.06% less ownership
Funds ownership: 117.48% → 117.42% (-0.06%)
21% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 108
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$22.5M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$21.7M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$21.3M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$13.2M |
| 5 |
D.E. Shaw & Co
New York
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$55.6M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$21.5M |
| 3 |
Walleye Capital
New York
|
-$7.93M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.68M |
| 5 |
Goldman Sachs
New York
|
-$6.47M |
COLL Hedge Fund Activity: Q4 2025 in Review
278 of the 8,265 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q4 2025, worth a combined $1.72B — up 33% from $1.3B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new COLL positions and 16 closed out — a net gain of 36 holders — while 85 added to existing stakes and 108 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $22.5M. The largest seller was Rubric Capital Management (New York), cutting an estimated $55.6M.
- 278 institutional investors held Collegium Pharmaceutical (COLL) as of Q4 2025, up from 244 in Q3 2025.
- Funds reported $1.72B of Collegium Pharmaceutical stock for Q4 2025, up 33% quarter-over-quarter.
- 52 funds opened new Collegium Pharmaceutical positions in Q4 2025 and 16 closed out, a net change of +36 holders.
- The largest Collegium Pharmaceutical buyer in Q4 2025 was Janus Henderson Group, an estimated $22.5M added.
- The largest Collegium Pharmaceutical seller in Q4 2025 was Rubric Capital Management (New York), an estimated $55.6M sold.
Based on aggregated 13F filings for Q4 2025.